Medtronic (MDT)’s CEO “is One of the Finest People,” Says Jim Cramer

Core Viewpoint - Medtronic plc (NYSE:MDT) is experiencing strong performance in its fiscal year 2026, with revenue growth projected at 5.5% and earnings per share (EPS) guidance set between $5.62 and $5.66, indicating positive momentum in the medical technology sector [2]. Company Performance - Medtronic reported $9 billion in revenue for the fiscal second quarter, surpassing analyst expectations, with earnings of $1.36 per share [2]. - The CEO, Geoffrey Martha, attributes the strong performance to the overall strength in medical procedures, highlighting the company's advancements in various medical fields [2]. Market Sentiment - Jim Cramer expressed optimism about Medtronic, referring to the CEO as "one of the finest people" and indicating that the stock is a buy despite its current price level [2][3]. - Cramer noted that Medtronic is well-positioned in areas such as ablations and diabetes, and praised the company's efforts in neuroscience, emphasizing the need for breakthroughs in this challenging field [2].